The SPC notes that the clinical relevance if this interaction is unknown, but data indicate the potential for reduced prasugrel efficacy in patients co-administered prasugrel and morphine. It suggest that in patients with ACS, in whom morphine cannot be withheld and fast P2Y12 inhibition is deemed crucial, the use of a parenteral P2Y12 inhibitor may be considered.